Background: Pseudomonas aeruginosa is not a frequent pathogen in Community Acquired Pneumonia (CAP). However, in patients with severe CAP, P. aeruginosa can be the etiology in 1.8% to 8.3% of patients, with a case-fatality rate of 50% to 100%.
Pseudomonas aeruginosa is not a frequent pathogen in community-acquired pneumonia (CAP) [1] [2] [3] [4] . Several studies have reported that P. aeruginosa was the cause in 1.8% to 8.3% of patients with severe CAP requiring intensive care unit (ICU) admission, with a case-fatality rate of 50% to 100% 5-9 . Since antibiotic treatment for P. aeruginosa is completely different from the standard treatment to cover common pathogens in CAP (Streptococcus pneumoniae, Legionella pneumophila, and atypical bacteria), current guidelines for severe CAP stratify therapy recommendations on the basis of Pseudomonal risk factors. However, since those guidelines were published, highly resistant forms of this pathogen have emerged, and for these patients, treatment is even more difficult. Many years ago, our group published a study 10 on P. aeruginosa in CAP. In that study, the prevalence of P. aeruginosa was 6.9% and mortality was 28%.
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METHODS
Study Design and Patients
We performed an observational cohort study of consecutive patients admitted to Hospital Clinic, Barcelona, Spain, between January 1999 and December 2014 with a diagnosis of community-acquired pneumonia. The exclusion criteria were: a) patients without a positive microbiologic diagnosis, b) severe immunosuppression (AIDS, chemotherapy, immunosuppressive drugs [e.g., oral corticosteroid ≥10 mg prednisone or equivalent per day for at least two weeks]), c) health care-associated pneumonia cases, d) active tuberculosis, e) patients with cystic fibrosis, and f) cases with a confirmed alternate diagnosis (additional details are shown in e-Methods in Supplementary Data). We include nursing home patients for the following reasons: 1-In Spain, the definition of nursing-home is very heterogeneous and it is unclear if all these would belong to an HCAP group. 2-In a previous article published by our group in Thorax (Polverino et al 11 ) on nursing-home patients, we observed that microbial etiology was not very different compared to CAP. The study was approved by the Ethics Committee of our institution (Register: 2009/5451). Written informed consent was waived due to the non-interventional design.
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Definitions
Pneumonia was defined as a new pulmonary infiltrate found on the hospital admission chest x-ray, with symptoms and signs of lower respiratory tract infection (e.g., fever, cough, sputum production, pleuritic chest pain) in persons who have not been hospitalized recently and have not had regular exposure to the health care system. P. aeruginosa pneumonia was defined as pneumonia where P. aeruginosa was isolated in blood or in a valid respiratory sample (see Supplementary data).
Prior antibiotic treatment was considered when antibiotics had been taken in the previous month. Appropriateness of empiric antibiotic treatment in all patients was defined according to multidisciplinary guidelines for the management of community acquired pneumonia 14 . Appropriateness of empiric antimicrobial treatment in patients was defined when the isolated pathogens were susceptible in vitro to ≥1 of the antimicrobials administered, except in the case of P. aeruginosa. For P. aeruginosa infection, initial appropriate empiric treatment required two antibiotics active against the isolated strain 15 .
Resistance of P. aeruginosa to multiple antibiotics was defined as Multi-drug resistant (MDR), extensively drug-resistant (XDR) or pandrug-resistant (PDR), as described else where 16 .
Polymicrobial pneumonia was defined when more than one pathogen was identified as the causative agent M A N U S C R I P T
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Severe CAP was defined when at least one major or 3 minor criteria of the Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines were present 17 . Chronic respiratory disease was defined as treatment for asthma, simple chronic bronchitis or chronic obstructive disease (COPD defined as a documented irreversible airflow obstruction); bronchiectasis or the presence of interstitial lung disorders.
Microbiological Evaluation
Microbiologic examination was performed on sputum, urine, two samples of blood and nasopharyngeal swabs. Pleural fluid, tracheobronchial aspirates (TBAS) and bronchoalveolar lavage (BAL) fluid, when available, were collected for Gram and Ziehl-Nielsen stains and for cultures for bacterial, fungal and mycobacterial pathogens.
Sputum (see supplementary data) and blood samples were obtained for bacterial culture before the start of antibiotic therapy in the emergency department.
Nasopharyngeal swab for respiratory virus detection was collected when available; urine samples for Streptococcus pneumoniae and Legionella pneumophila antigen detection were obtained within 24 hours after hospital admission. Blood samples for serology of atypical pathogens and respiratory virus were collected at admission and between the third and sixth week thereafter.
Routine antimicrobial susceptibility testing included the Phoenix system (Becton Dickinson, MD, USA) for P. aeruginosa isolated from blood cultures and the disk diffusion method or E-test for P. aeruginosa isolated from respiratory samples.
Results of susceptibility testing were interpreted according to EUCAST guidelines 18 .
Statistical Analysis
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We report the number of patients (%) for categorical variables, the median (1st quartile; 3rd quartile) for continuous variables with non-normal distribution, and the mean (SD) for those with normal distribution. Categorical variables were compared using the χ 2 test or the Fisher exact test. Continuous variables were compared using the t test or the nonparametric Mann-Whitney test. Univariate and multivariate logistic regression analyses were performed to identify variables associated with the presence of CAP due to P. aeruginosa (see supplementary data for the full list of variables); we performed a subgroup analysis for patients with chronic respiratory disease.
Also univariate and multivariate logistic regression analyses were performed to identify variables associated with MDR in patients with P. aeruginosa. Variables that showed a significant result in the univariate analysis (p<0.1) were included in the corresponding multivariate logistic regression backward stepwise model. Strongly correlated variables were excluded from multivariate analyses. The association with 30-day mortality was also tested by means of univariate and multivariate analysis, and similar inclusion criteria were applied for the logistic regression analysis (p<0.1); we performed a subgroup analysis for patients with P. aeruginosa. The Hosmer-Lemeshow goodness-of-fit test was performed to assess the overall fit of the model 19 . Internal validation of the prediction models was conducted using ordinary nonparametric bootstrapping with 1000 bootstrap samples and bias-corrected, accelerated 95% confidence intervals (CIs). Receiver operating characteristic (ROC) curves were constructed for the ability to predict patients with CAP due to P. aeruginosa, patients with CAP due to MDR P. aeruginosa, and 30-day mortality, using significant variables derived from the respective logistic regression model. All tests were 2-tailed and 
RESULTS
Patient Characteristics
A total of 5384 consecutive patients with CAP were enrolled during the study period. The final study population consisted of 2023 patients with an established microbial etiology (Figure 1 ). There were 1253 (62%) males and the mean (SD) age was 65 (19) years. CAP was due to P. aeruginosa in 77 of 2023 cases (4%). Sixty-eight cases of the 77 (88%) had susceptibility data, and 22 (32%) were multidrug resistant (MDR) P. aeruginosa and 46 (68%) were non MDR P. aeruginosa. We did not find XDR or PDR strains of P. aeruginosa.
On average, patients with CAP due to P. aeruginosa were older and more frequently males, received prior antibiotics and inhaled corticosteroids more often, had a higher proportion of chronic respiratory disease, especially chronic obstructive pulmonary disease (COPD), and were more likely to have a history of a previous episode of pneumonia, compared to those with other pathogens (Table 1) . They also had a more severe clinical presentation (respiratory rate, respiratory failure) at admission, but less fever, less pleuritic pain and lower levels of C-reactive protein. A total of 23% were admitted to the ICU, which is not significantly higher than in other CAP patients. A higher percentage of patients with CAP due to P. aeruginosa was in PSI risk class IV-V and CURB-65 class 3-5 than patients with CAP caused by other pathogens. The 30-day mortality rate was significantly higher in patients with CAP due to P. aeruginosa (18 % vs. 6%, p<0.001).
The differences in baseline characteristics between MDR and non-MDR P.
aeruginosa CAP are summarized in Table 2 . MDR P. aeruginosa CAP patients had M A N U S C R I P T
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received prior antibiotics significantly more often (58% vs. 29%, p=0.029) and the rate of pneumonia in the previous year was also higher (46% vs. 21%, p=0.034).
Microbiology
In the group of patients with CAP caused by other pathogens, the five most frequent pathogens were Streptococcus pneumoniae ( Susceptibility testing was performed in 68 of the 77 P. aeruginosa isolates (88%). Thirty-two isolates (47%) showed in-vitro resistance to ciprofloxacin, 15 (24%) were resistant to piperacillin-tazobactam, 16 (24%) to gentamicin, 14 (24%) to tobramycin, 15 (22%) to ceftazidime, 15 (22%) to imipenem, 15 (22%) to meropenem, 7 (11%) to colistin, and 2 (3%) to amikacin. Twenty-two strains (32%) were classified as MDR P. aeruginosa.
Antibiotic Treatment
Data on antibiotic treatment was available in 1965 patients (97%). In general, the most frequent regimens were a combination of a cephalosporin plus a macrolide The empiric antimicrobial treatment was inadequate in 206 of all cases (13%).
In the group with CAP due to P. aeruginosa, 49 cases (64%) had inadequate empiric antimicrobial treatment (3 cases were inadequate because only one correct antibiotic was used) compared to the 157 cases (10%) in the group with CAP due to other pathogens (p<0.001). Seventeen of the 22 MDR cases (77%) were treated inadequately compared to the 28 of the 46 non-MDR cases (61%) (p=0.18).
Outcomes
Severe CAP was significantly more frequent in the group of CAP due to P. aeruginosa (62% vs. 28%, p<0.001) compared with the group of other pathogens, but use of the ICU was similar in both groups. Thirty-day mortality was significantly higher for patients with CAP due to P. aeruginosa, compared with the group of other pathogens (18% vs. 6%, p<0.001). Length of hospital stay was longer in CAP due to P. aeruginosa compared with CAP due to other microorganisms (7 [5; 12] vs. 13 [7; 16.5] days, p<0.001) (Table 1) . Also, there was a longer median length of hospital stay of the MDR group compared with non-MDR P. aeruginosa CAP (14 [12; 21] vs. 11 [7; 16] days, p=0.046) ( Table 2) .
Clinical Factors Associated With CAP Due to P. aeruginosa
Several variables were significantly associated with CAP due to P. aeruginosa in the univariate logistic regression analyses (Table 3) In the subgroup of patients with chronic respiratory disease, previous treatment with inhaled corticosteroids was the only variable associated with CAP due to P. aeruginosa in the multivariate analysis (e- Table 3 ). The area under the ROC curve was 0.62 (95% CI 0.52-0.71).
Associations of CAP Due to MDR P. aeruginosa
In the subgroup of CAP due to P. aeruginosa patients, the only risk factor associated with CAP due to MDR P. aeruginosa in the multivariate analysis was prior antibiotic treatment (Table 4 ). The area under the ROC curve was 0.64 (95% CI 0.49-0.80).
Predictors of 30-Day Mortality
In the multivariate logistic regression analysis, the following factors were independently associated with 30-day mortality: CAP due to P. aeruginosa, age ≥65 years, chronic liver disease, neurologic disease, nursing home, acute renal failure, ICU admission, and inappropriate initial empiric treatment ( Table 5 ). The area under the ROC curve was 0.86 (95% CI 0.82-0.90) for the model predictive of 30-day mortality.
In the subgroup of CAP due to P. aeruginosa patients, previous treatment with inhaled corticosteroids and acute renal failure were the variables associated with 30day mortality in the multivariate analysis (e- Table 4 ). The area under the ROC curve was 0.83 (95% CI 0.72-0.95).
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DISCUSSION
The main findings of this study are the following: 1.-The prevalence of CAP due to P. aeruginosa in this large series of consecutive patients with CAP was 4% of patients with a defined etiology, and 32% of these patients had MDR P. aeruginosa. 2.-We identified several risk factors associated with CAP due to P. aeruginosa in general and for CAP due to MRD P. aeruginosa. 3.-CAP due to P. aeruginosa was associated with a significantly higher rate of inappropriate therapy than CAP due to other pathogens (65% vs. 11%; p<0.001). 4.-CAP due to P. aeruginosa was associated with CAP mortality in a multivariate model.
The prevalence of 4% found in our study is higher than other studies, but this was only for patients with an established etiology and for the entire population, the frequency was 1.2%. In another report from Spain, 20 the prevalence was 1.5% in patients with microbial etiology. In a large retrospective study from San Antonio, 21 the prevalence of P. aeruginosa was 1.1%.
If we compare the current results with the article from our group published more than 10 years earlier, corresponding to the 1997-1998 period, the prevalence of M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
we provide data and differential characteristics regarding MDR versus non-MDR
Pseudomonas aeruginosa
Only two studies have investigated risk factors for P. aeruginosa CAP in multivariate analyses. We identified four risk factors in the multivariate analysis. In our previous study in 2002, 22 we did not perform a multivariate analysis but we found that P. aeruginosa was associated with male sex, previous hospital admission, pulmonary comorbidity and ICU admission. From all this information, it appears that the key factor is chronic respiratory disease. In the absence of chronic respiratory disease, there is probably no need for empiric therapy to cover P. aeruginosa in immunocompetent patients.
In addition, we performed a multivariable analysis to determinate risk factors for P. aeruginosa in the population with chronic respiratory conditions and found that the use of inhaled corticosteroids was the only risk factor for P. aeruginosa pneumonia in this population. Overall, inhaled corticosteroids are a well-defined risk factor for CAP and possibly for a specific pathogen such as P. aeruginosa.
An important finding of our study is that that P. aeruginosa was MDR in 32% of the isolates with antibiogram data. This has not been previously reported and the only risk factor associated with P. aeruginosa MDR was previous antibiotic treatment. A clinical consequence of this finding is to use antibiotics covering MDR Pseudomonas when P. aeruginosa is suspected and there is prior antibiotic treatment.
The raw mortality of P. aeruginosa CAP was 18% in our series, similar to a recent manuscript published in Respirology 23 . P. aeruginosa was an independent factor associated with mortality even after adjustment for inadequate antibiotic treatment.
In the subpopulation of MDR P. aeruginosa, P. aeruginosa was not a factor associated M A N U S C R I P T
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with mortality, suggesting that these resistant strains, although more difficult to treat, may be less virulent 24;25 . Previous inhaled corticosteroids were independently associated with higher mortality (OR, 12.80) in this subpopulation, which contrasts with previous reports that found inhaled corticosteroids to be protective for complications and mortality 26;27 .
We published in 1991 a manuscript in which we observed that Pseudomonas was associated with higher independently mortality. However, that series included only 5 cases of Pseudomonas CAP which makes very difficult to compare with the presented study in which we included 77 cases 5 .
Our study has 2 major limitations. First, it is a single-center study in a teaching hospital covering a population of more than half a million persons. This may not apply to other hospitals with different populations. Second, this was a 12-year study, but the standards for diagnosing P. aeruginosa CAP have not varied during that period. The major strengths of the study are that it is a very large series of CAP patients and that we studied the resistance patterns of most of the P. aeruginosa isolates and found data that may be helpful in guiding empiric therapy of CAP in the current era of drugresistant P. aeruginosa.
Conclusions
In summary, we found that, while not common, Pseudomonas aeruginosa was a cause of CAP and one that is often treated inappropriately (64% of patients). Some 32% of cases are have multidrug resistant, and these patients need to be identified because we found that 77% received inappropriate empiric therapy. Compared to other forms of CAP, patients with P. aeruginosa had severe disease more commonly (62% vs. 28%). In this series, as in others, inappropriate empiric antibiotic therapy was M A N U S C R I P T
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a mortality risk for all patients with CAP, so identification of patients requiring special therapy, such as those with P. aeruginosa, is essential to assure correct therapy choices. Those most at risk for P. aeruginosa were patients with chronic respiratory disease, particularly those receiving inhaled corticosteroids, although patients receiving high dose systemic corticosteroids were excluded from this analysis.
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